First-In-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR In Patients With Advanced Cancer

PURPOSE: To evaluate safety (primary endpoint), tolerability, pharmacokinetics, pharmacodynamic profile, and preliminary activity of the intravenous, pan-class I isoform PI3K/mTOR inhibitor PF-05212384 in patients with advanced solid tumors. EXPERIMENTAL DESIGN: Part 1 of this open-label phase I stu...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clin Cancer Res
Hauptverfasser: Shapiro, Geoffrey I., Bell-McGuinn, Katherine M., Molina, Julian R., Bendell, Johanna C., Spicer, James, Kwak, Eunice L., Pandya, Susan, Millham, Robert, Borzillo, Gary, Pierce, Kristen, Han, Lixin, Houk, Brett, Gallo, Jorge D., Alsina, Maria, Braña, Irene, Tabernero, Josep
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2015
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4508327/
https://ncbi.nlm.nih.gov/pubmed/25652454
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-1306
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge